Prime Medicine (PRME) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.24
- Estimate
- -$0.26
- Surprise
- +6.0%
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Prime Medicine (PRME) reported a narrower loss than forecast — diluted EPS of -$0.24 against the -$0.26 estimate (a 6.0% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates PRME Sell at 4.9/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +6.0% surprise compares with a -7.3% four-quarter average. Next scheduled report: 2026-11-06.
What argues against it
- Quality below floor (2.3 < 4.0)
- Value-trap signals (2/5): Material insider selling (38 sells, 0.26% of cap), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.39
- Price target
- $6.35
- Stop
- $3.15
- Upside to target
- +87.3%
- Reward-to-risk
- 5.8:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
PRME at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $614.9M
- P/E (fwd)
- -3.8
- 52-week range
- $2.67–$6.94
- Off 52-week high
- 51.2%
- RSI (14)
- 64
- Volume vs avg
- 1.32×
- Score today
- 4.9/10